{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:59:18Z","timestamp":1787979558262,"version":"build-2784847793"},"reference-count":36,"publisher":"American Society of Hematology","issue":"21","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients treated with deferiprone for transfusional iron overload may experience idiosyncratic drug\u2013induced neutropenia (IDIN) that may increase risk of infection. This analysis examined the rates of severe IDIN and risk of serious infections at different absolute neutrophil count (ANC) levels during deferiprone treatment. Events of severe IDIN (ANC\u00a0&amp;lt;0.5\u00a0\u00d7 109\/L) and associated serious infections from clinical trials and postmarketing setting were analyzed by discrete ANC levels: group 1, 0.2\u00a0\u00d7 109\/L to 0.5\u00a0\u00d7 109\/L; group 2, 0.1\u00a0\u00d7\u00a0109\/L to 0.199\u00a0\u00d7 109\/L; group 3, &amp;lt;0.1\u00a0\u00d7 109\/L. In clinical trials, 22 events of severe IDIN occurred (group 1, n\u00a0= 9; group 2, n\u00a0= 3; group 3, n\u00a0= 10), and rates of severe IDIN per 100 patient-years were 0.45 in group 1; 0.15 in group 2; and 0.50 in group 3 (1990.26 patient-years deferiprone exposure). All serious infections were in group 3 (3\/10 [30.0%]). In the postmarketing setting, 176 events of severe IDIN were reported (group 1, n\u00a0= 65; group 2, n\u00a0=\u00a020; group 3, n\u00a0= 91) and rates of severe IDIN per 100 patient-years were 0.06 in group 1; 0.02 in group 2; and 0.08 in group 3 (111 570.24 patient-years deferiprone exposure). Rates of serious infection were 7.7% (5\/65) in group 1; 10% (2\/20) in group 2; and 13.2% (12\/91) in group 3. Our findings suggest a high risk of serious infections with ANC &amp;lt;0.2 \u00d7 109\/L during deferiprone treatment, a level consistent with the recent neutropenia guidelines.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012316","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T19:20:56Z","timestamp":1713554456000},"page":"5641-5649","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4739-265X","authenticated-orcid":false,"given":"Sherif M.","family":"Badawy","sequence":"first","affiliation":[{"name":"1Division of Hematology, Oncology, and Stem Cell Transplant, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, IL"},{"name":"2Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4014-2540","authenticated-orcid":false,"given":"Jan","family":"Palmblad","sequence":"additional","affiliation":[{"name":"3Departments of Medicine and Hematology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Tricta","sequence":"additional","affiliation":[{"name":"4Hematology\/Immunology Program, Chiesi Global Rare Diseases, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Toiber Temin","sequence":"additional","affiliation":[{"name":"4Hematology\/Immunology Program, Chiesi Global Rare Diseases, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Fradette","sequence":"additional","affiliation":[{"name":"4Hematology\/Immunology Program, Chiesi Global Rare Diseases, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Lin","sequence":"additional","affiliation":[{"name":"4Hematology\/Immunology Program, Chiesi Global Rare Diseases, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rozova","sequence":"additional","affiliation":[{"name":"4Hematology\/Immunology Program, Chiesi Global Rare Diseases, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7640-1244","authenticated-orcid":false,"given":"Sujit","family":"Sheth","sequence":"additional","affiliation":[{"name":"5Division of Pediatric Hematology\/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"issue":"9","key":"2024111213553157000_bib1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","article-title":"Systematic review: agranulocytosis induced by nonchemotherapy drugs","volume":"146","author":"Andersohn","year":"2007","journal-title":"Ann Intern Med"},{"issue":"5","key":"2024111213553157000_bib2","first-page":"299","article-title":"Idiosyncratic drug-induced neutropenia & agranulocytosis","volume":"110","author":"Andres","year":"2017","journal-title":"QJM"},{"issue":"2","key":"2024111213553157000_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"issue":"7","key":"2024111213553157000_bib4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ajh.21433","article-title":"Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management","volume":"84","author":"Tesfa","year":"2009","journal-title":"Am J Hematol"},{"key":"2024111213553157000_bib5","doi-asserted-by":"crossref","first-page":"727717","DOI":"10.3389\/fphar.2021.727717","article-title":"Drug-induced idiosyncratic agranulocytosis--infrequent but dangerous","volume":"12","author":"Rattay","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"2024111213553157000_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MOH.0b013e3282f15fb9","article-title":"Idiosyncratic drug-induced agranulocytosis or acute neutropenia","volume":"15","author":"Andres","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"2024111213553157000_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/asheducation.V2012.1.174.3798251","article-title":"How to approach neutropenia","volume":"2012","author":"Boxer","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2024111213553157000_bib8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/asheducation-2017.1.187","article-title":"Non-chemotherapy drug-induced neutropenia: key points to manage the challenges","volume":"2017","author":"Curtis","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2024111213553157000_bib9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/0897190014546115","article-title":"Nonchemotherapy drug-induced neutropenia and agranulocytosis: could medications be the culprit?","volume":"27","author":"Pick","year":"2014","journal-title":"J\u00a0Pharm Pract"},{"issue":"4","key":"2024111213553157000_bib10","doi-asserted-by":"crossref","first-page":"e872","DOI":"10.1097\/HS9.0000000000000872","article-title":"The European guidelines on diagnosis and management of neutropenia in adults and children: a consensus between the European Hematology Association and the EuNet-INNOCHRON COST action","volume":"7","author":"Fioredda","year":"2023","journal-title":"Hemasphere"},{"issue":"5","key":"2024111213553157000_bib11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jcpt.12422","article-title":"Safety of metamizole: a systematic review of the literature","volume":"41","author":"Andrade","year":"2016","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"4","key":"2024111213553157000_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1365-2796.1990.tb00245.x","article-title":"Trimethoprim-sulphamethoxazole-associated blood dyscrasias. Ten years' experience of the Swedish spontaneous reporting system","volume":"228","author":"Keisu","year":"1990","journal-title":"J\u00a0Intern Med"},{"issue":"12","key":"2024111213553157000_bib13","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1182\/blood-2007-02-065805","article-title":"Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia","volume":"109","author":"Henter","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2024111213553157000_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/bjh.18366","article-title":"Agranulocytosis in patients with Diamond-Blackfan anaemia (DBA) treated with deferiprone for post-transfusion iron overload: a retrospective study of the French DBA cohort","volume":"199","author":"Lecornec","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"2024111213553157000_bib15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/03630269.2016.1276929","article-title":"A\u00a0case of fatal agranulocytosis that developed in a patient with beta-thalassemia major treated with deferiprone","volume":"40","author":"Mainou","year":"2016","journal-title":"Hemoglobin"},{"issue":"4","key":"2024111213553157000_bib16","first-page":"462","article-title":"Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination","volume":"9","author":"Masera","year":"2011","journal-title":"Blood Transfus"},{"key":"2024111213553157000_bib17","unstructured":"FERRIPROX (deferiprone) tablets, for oral use. Prescribing information. Chiesi USA, Inc. 2021. https:\/\/resources.chiesiusa.com\/Ferriprox\/FERRIPROX_PI_US.pdf."},{"key":"2024111213553157000_bib18","unstructured":"FERRIPROX (deferiprone) oral solution, for oral use. Prescribing information. Chiesi USA, Inc. 2021. https:\/\/resources.chiesiusa.com\/Ferriprox\/FERRIPROX_OS_PI_MG_IFU_US.pdf."},{"issue":"1","key":"2024111213553157000_bib19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3324\/haematol.2017.176065","article-title":"Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study","volume":"103","author":"Botzenhardt","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"2024111213553157000_bib20","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/bloodadvances.2021006778","article-title":"Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years","volume":"7","author":"Elalfy","year":"2023","journal-title":"Blood Adv"},{"issue":"14","key":"2024111213553157000_bib21","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A\u00a0randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"issue":"10","key":"2024111213553157000_bib22","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ajh.24479","article-title":"Deferiprone-induced agranulocytosis: 20 years of clinical observations","volume":"91","author":"Tricta","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2024111213553157000_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.1995.tb05274.x","article-title":"Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators","volume":"91","author":"al-Refaie","year":"1995","journal-title":"Br J Haematol"},{"issue":"1","key":"2024111213553157000_bib24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.2002.03554.x","article-title":"The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients","volume":"118","author":"Ceci","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"2024111213553157000_bib25","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"issue":"9","key":"2024111213553157000_bib26","first-page":"1351","article-title":"State of art of idiosyncratic drug-induced neutropenia or agranulocytosis, with a focus on biotherapies","volume":"8","author":"Andres","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"4","key":"2024111213553157000_bib27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/ejh.12241","article-title":"Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count","volume":"92","author":"El-Beshlawy","year":"2014","journal-title":"Eur J Haematol"},{"issue":"6","key":"2024111213553157000_bib28","first-page":"1808","article-title":"Idiosyncratic drug-induced neutropenia and agranulocytosis in elderly patients","volume":"9","author":"Lorenzo-Villalba","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"2024111213553157000_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000204494","article-title":"Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one","volume":"89","author":"al-Refaie","year":"1993","journal-title":"Acta Haematol"},{"issue":"5","key":"2024111213553157000_bib30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1600-0609.1994.tb01323.x","article-title":"Deferiprone-associated myelotoxicity","volume":"53","author":"al-Refaie","year":"1994","journal-title":"Eur J Haematol"},{"issue":"8660","key":"2024111213553157000_bib31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(89)90641-7","article-title":"Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial","volume":"2","author":"Hoffbrand","year":"1989","journal-title":"Lancet"},{"issue":"4","key":"2024111213553157000_bib32","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/03630260701641211","article-title":"Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient","volume":"31","author":"Sheikh-Taha","year":"2007","journal-title":"Hemoglobin"},{"issue":"3","key":"2024111213553157000_bib33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1053\/j.seminhematol.2013.06.010","article-title":"Evaluation and management of patients with isolated neutropenia","volume":"50","author":"Newburger","year":"2013","journal-title":"Semin Hematol"},{"key":"2024111213553157000_bib34","first-page":"1495","article-title":"\u00dcber eigenartige halserkrankungen","volume":"48","author":"Shultz","year":"1922","journal-title":"Dtsch Med Wochenschr"},{"issue":"6","key":"2024111213553157000_bib35","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S2352-3026(20)30100-9","article-title":"Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial","volume":"7","author":"Maggio","year":"2020","journal-title":"Lancet Haematol"},{"issue":"4","key":"2024111213553157000_bib36","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/bloodadvances.2021004938","article-title":"Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study","volume":"6","author":"Kwiatkowski","year":"2022","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/21\/5641\/2312432\/blooda_adv-2023-012316-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/21\/5641\/2312432\/blooda_adv-2023-012316-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T13:56:01Z","timestamp":1731419761000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/21\/5641\/515792\/Rates-of-severe-neutropenia-and-infection-risk-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":36,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,11,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012316","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]}}}